CNS Pharmaceuticals (CNSP) Competitors $0.11 +0.01 (+5.41%) (As of 12/26/2024 05:41 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CNSP vs. CMMB, CVKD, NKGN, MTEX, IBIO, NNVC, EQ, CTXR, PULM, and GOVXShould you be buying CNS Pharmaceuticals stock or one of its competitors? The main competitors of CNS Pharmaceuticals include Chemomab Therapeutics (CMMB), Cadrenal Therapeutics (CVKD), NKGen Biotech (NKGN), Mannatech (MTEX), iBio (IBIO), NanoViricides (NNVC), Equillium (EQ), Citius Pharmaceuticals (CTXR), Pulmatrix (PULM), and GeoVax Labs (GOVX). These companies are all part of the "pharmaceutical products" industry. CNS Pharmaceuticals vs. Chemomab Therapeutics Cadrenal Therapeutics NKGen Biotech Mannatech iBio NanoViricides Equillium Citius Pharmaceuticals Pulmatrix GeoVax Labs Chemomab Therapeutics (NASDAQ:CMMB) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, community ranking, institutional ownership and dividends. Does the media favor CMMB or CNSP? In the previous week, Chemomab Therapeutics and Chemomab Therapeutics both had 3 articles in the media. Chemomab Therapeutics' average media sentiment score of 1.87 beat CNS Pharmaceuticals' score of 0.94 indicating that Chemomab Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Chemomab Therapeutics Very Positive CNS Pharmaceuticals Positive Which has more volatility and risk, CMMB or CNSP? Chemomab Therapeutics has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Comparatively, CNS Pharmaceuticals has a beta of 2.55, suggesting that its stock price is 155% more volatile than the S&P 500. Do institutionals and insiders believe in CMMB or CNSP? 46.0% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by company insiders. Comparatively, 0.1% of CNS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer CMMB or CNSP? Chemomab Therapeutics currently has a consensus price target of $7.50, indicating a potential upside of 276.88%. CNS Pharmaceuticals has a consensus price target of $0.50, indicating a potential upside of 335.16%. Given CNS Pharmaceuticals' higher possible upside, analysts clearly believe CNS Pharmaceuticals is more favorable than Chemomab Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50CNS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community believe in CMMB or CNSP? CNS Pharmaceuticals received 29 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. Likewise, 71.21% of users gave CNS Pharmaceuticals an outperform vote while only 64.29% of users gave Chemomab Therapeutics an outperform vote. CompanyUnderperformOutperformChemomab TherapeuticsOutperform Votes1864.29% Underperform Votes1035.71% CNS PharmaceuticalsOutperform Votes4771.21% Underperform Votes1928.79% Which has stronger earnings and valuation, CMMB or CNSP? Chemomab Therapeutics is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChemomab TherapeuticsN/AN/A-$24.22M-$1.00-1.99CNS PharmaceuticalsN/AN/A-$18.85M-$74.970.00 Is CMMB or CNSP more profitable? CNS Pharmaceuticals' return on equity of 0.00% beat Chemomab Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Chemomab TherapeuticsN/A -101.70% -76.18% CNS Pharmaceuticals N/A N/A -515.32% SummaryChemomab Therapeutics and CNS Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get CNS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNSP vs. The Competition Export to ExcelMetricCNS PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.61M$6.68B$5.24B$9.26BDividend YieldN/A2.98%5.11%4.26%P/E Ratio0.0010.6887.6117.33Price / SalesN/A209.011,162.83123.73Price / CashN/A57.1543.3737.83Price / Book0.005.254.905.06Net Income-$18.85M$150.75M$120.44M$225.13M7 Day Performance6.39%4.44%3.00%4.58%1 Month Performance-0.43%-3.67%16.91%3.45%1 Year Performance-99.82%7.59%27.89%17.94% CNS Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNSPCNS Pharmaceuticals2.8099 of 5 stars$0.11+5.4%$0.50+335.2%-99.8%$6.61MN/A0.005Short Interest ↓News CoverageGap UpCMMBChemomab Therapeutics3.2504 of 5 stars$1.65-1.8%$7.50+354.5%+290.2%$23.69MN/A-1.6520Short Interest ↑CVKDCadrenal Therapeutics2.5021 of 5 stars$14.26-11.8%$32.00+124.4%N/A$23.66MN/A-2.144Short Interest ↑NKGNNKGen BiotechN/A$0.64+0.4%N/A-69.0%$22.73M$80,000.00-0.13N/AMTEXMannatech0.2674 of 5 stars$11.59-2.4%N/A+33.2%$21.85M$121.55M-14.31250Gap UpIBIOiBio1.3155 of 5 stars$2.36-4.8%$4.30+82.2%N/A$21.59M$175,000.000.00100Gap DownNNVCNanoViricidesN/A$1.53+2.7%N/A+45.2%$21.34MN/A-2.0120Gap UpHigh Trading VolumeEQEquillium2.9291 of 5 stars$0.60-1.6%$5.00+736.1%-0.5%$21.19M$45.91M-4.2740Short Interest ↓Gap DownCTXRCitius Pharmaceuticals3.2986 of 5 stars$2.91+11.9%$100.00+3,336.4%-83.2%$21.04MN/A-0.4920Short Interest ↓PULMPulmatrix0.1493 of 5 stars$5.76-4.0%N/A+221.0%$21.04M$10.01M-2.1820Short Interest ↑Gap DownGOVXGeoVax Labs2.7735 of 5 stars$2.21-3.5%$14.20+542.5%-57.1%$20.85M$3.09M0.0017Short Interest ↑ Related Companies and Tools Related Companies CMMB Competitors CVKD Competitors NKGN Competitors MTEX Competitors IBIO Competitors NNVC Competitors EQ Competitors CTXR Competitors PULM Competitors GOVX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CNSP) was last updated on 12/27/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
